Abstract LB281: Mechanisms of resistance to the RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS(ON) combination therapies

Authors: Sumit Kar, Yongxian Zhuang, Ethan Ahler, Lick P. Lai, Alexander Starodub, Alexander Spira, Salman R. Punekar, Ignacio Garrido-Laguna, Wungki Park, David S. Hong, Anirban Maitra, David Sommerhalder, Minal Barve, Meredith Pelster, Harika Gundlapalli, Vidya Seshadri, Shurui Cai, Mark Labrecque, Wan-Ying Hsieh, Sean Bredeson, Jim Evans, Brett Garrick, Yevgeniy Gindin, Cristina Blaj, Marie Menard, Lingyan Jiang, Elsa Quintana, Matthew Holderfield, Aparna Hegde, Jingjing Jiang, Zeena Salman, W Clay Gustafson, Jacqueline A. Smith, Brian Wolpin, Ida Aronchik, Kevin K. Lin, Andrew J. Aguirre, Mallika Singh

Published: 2025-04-25

DOI: 10.1158/1538-7445.am2025-lb281

Source: Full article